Study: Brain Cells Have Death System
Posted on: Wednesday, 1 March 2006, 15:00 CST
Harvard Medical School scientists in Boston announced Wednesday they have identified a protein that directly regulates cell death in the brain.
The say their finding raises the possibility a reduction in the expression of that protein in vulnerable neurons may protect them from undergoing cell death in many neurological disorders, including stroke and neurodegenerative diseases.
An understanding of neural-specific mechanisms of cell death is likely to be invaluable in the development of potential therapies for a variety of devastating neurological diseases, said Dr. Azad Bonni, a professor of pathology and the study's co-author.
Programmed cell death, or apoptosis, culls unneeded cells during development and growth and so protects an organism by triggering suicide in defective cells. Later in life, cells too quick to self-destruct may contribute to neurodegenerative diseases and immunodeficiency disorders.
The research is detailed in the March 2 issue of the journal Neuron.
Source: United Press International
Related Articles
- Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
- Potential Cure for Children With Sickle Cell Disease Evaluated in Nationwide Research Study
- Children Can Be Cured of Sickle Cell Disease and Thalassemia After Sibling Cord Blood Transplantation: Results From ViaCell and Children's Hospital & Research Center Oakland
- New Studies in Patients With Sickle Cell Disease Who Develop Pulmonary Hypertension-Recruiting Now for Clinical Trials
- Blood Test Detects Sickle Cell Disease Prognosis
- New York Blood Center Urges African Americans to Donate Blood to Help Prevent, Treat Many Complications of Life-Threatening Sickle Cell Disease
- Childrens Hospital Los Angeles Hosts a Symposium on Sickle Cell Disease
- Tracing Sickle Cell Disease
- Bone Area and Bone Mineral Content Deficits in Children With Sickle Cell Disease
- Icagen Initiates Enrollment in Pivotal Phase III Trial of ICA-17043 for the Treatment of Sickle Cell Disease
 |
 |
User Comments (0)
RSS Feeds